Fierce Biotech

GSK and Relation Therapeutics entered a research collaboration on July 30 worth up to $110 million to generate human cellular perturbation datasets and train AI foundation models for drug-target disco…

Axiom Biosciences, a San Diego-based clinical-stage biotech, plans a Hong Kong IPO in 2027 targeting at least $200 million, followed by a U.S. secondary listing in 2029, citing deep biotechnology capi…